VCNX Vaccinex Inc.

6.89
+1.81  (+36%)
Previous Close 5.08
Open 5.25
Price To Book -5.11
Market Cap 102,475,699
Shares 14,862,536
Volume 163,253
Short Ratio
Av. Daily Volume 5,809
Stock charts supplied by TradingView

NewsSee all news

  1. Vaccinex Announces $3 Million Award from the Alzheimer's Drug Discovery Foundation

    ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that

  2. Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer's Disease

    ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and nuerodegenerative diseases,

  3. Vaccinex Announces Award Notice from the Alzheimer's Association 2020 Part the Cloud Program

    Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington's disease, will be tested for similar effects in Alzheimer's disease ROCHESTER, N.Y., Nov. 14,

  4. Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study

  5. Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington's disease, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due 4Q 2020.
VX15 - Signal
Huntington’s disease
Phase 1/2 trial to be completed 2H 2020.
VX15 Yervoy and Opdivo
Melanoma
Phase 1/2 top-line data due 1H 2020.
Pepinemab (VX15) and avelumab
Non-small cell lung cancer (NSCLC)
Phase 1 enrolment to commence 2Q 2020 with top-line data late 2021 or early 2022.
Pepinemab (VX15/2503)
Alzheimer’s Disease (AD)

Latest News

  1. Vaccinex Announces $3 Million Award from the Alzheimer's Drug Discovery Foundation

    ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that

  2. Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer's Disease

    ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and nuerodegenerative diseases,

  3. Vaccinex Announces Award Notice from the Alzheimer's Association 2020 Part the Cloud Program

    Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington's disease, will be tested for similar effects in Alzheimer's disease ROCHESTER, N.Y., Nov. 14,

  4. Vaccinex Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected by the end of 2019 Updated interim data from the CLASSICAL-Lung study

  5. Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    ROCHESTER, N.Y., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington's disease, today

  6. Orgenesis Appoints Bala S. Manian to its Scientific Advisory Board

    GERMANTOWN, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development

  7. Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France

    ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington's disease, today

  8. Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington's disease, today